Biopharma's focus on rare conditions and financial reward, exemplified:
A rare disease—primary AATR cardiac amyloidosis—is the subject of an emerging 3-way treatment competition for many $ billions per year. https://
wsj.com/health/pharma/
the-brawl-taking-shape-over-pfizers-multibillion-dollar-heart-monopoly-43a220c2?mod=Searchresults_pos1&page=1
… @pfizer @BridgeBioPharma @Alnylam
@erictopol
-
Biopharma Competition for Rare Cardiac Amyloidosis Treatment Market
By
–
-
OpenAI Strawberry Excels in AgentClinic Benchmarking
By
–
Strawberry @OpenAI is looking quite good in benchmarking by AgentClinic! https://
agentclinic.github.io -
DebunkBot: AI Chatbot Fights Conspiracy Theories
By
–
More on DebunkBot
gift link https://
nytimes.com/2024/09/12/hea
lth/chatbot-debunk-conspiracy-theories.html?unlocked_article_code=1.KU4.HRJ9.wZoqVG75yMmK&smid=url-share
…
by @teddyrosenbluth -
RCT Methodology Versus Observational Studies in AI Research
By
–
Agree to be skeptical. Also RCT vs hodgepodge observational study, but it’s an interesting report
-
GLP-1 Drugs Study Obesity Patients Without Diabetes
By
–
TriX Global Network with index event between 1 January 2016 and 31 March 2024. Details are in the paper and supplemental info, includes any GLP-1 drug new user for at least 6 months in people with obesity, without diabetes
-
AI Reduces Heart Disease, Stroke, Kidney Disease Outcomes
By
–
Other outcomes assessed. Significant reductions of ischemic heart disease (IHD), stroke, heart failure, arrhythmias, atrial fibrillation, acute and chronic kidney disease, allergic reactions
-
Spatial Omics Reveals T Cells Driving Atrial Fibrillation Inflammation
By
–
An spatial omics discovery example from this week
In the fat tissue surrounding the heart, there are resident memory T cells that promote inflammation, prominent in people with atrial fibrillation, that helps explain vulnerability to this common arrhythmia https://
nature.com/articles/s4416
1-024-00532-x
… -
Recent paper on maximal lifespan discussed
By
–
We discussed his important recent paper on maximal lifespan
-
Epigenetic Aging Clocks: Progress, Limitations, and Medical Promise
By
–
Epigenetic aging clocks have become a commonly used metric in medical research and are being marketed to consumers. The new Ground Truths with @prof_horvath
, who discovered these clocks a decade ago, provides a frank appraisal of their progress, limitations, and promise. With -
LLMs Eliminate Need for Traditional Coding System Standardization
By
–
In the era of large language models: "The extensive efforts previously required to standardize and make coding systems and ontologies interoperable for traditional computing are no longer necessary." https://
nature.com/articles/s4159
1-024-03199-w
…
by @jnkath @DanielTruhn @Dykex6 @IsabellaWies